Dihexa Peptide: Research Overview, Purity Data and Where to Buy

Dihexa is not a stimulant, not a secretagogue, and not a receptor agonist in the conventional sense. The preclinical literature describes it as an angiotensin IV analog that behaves as a positive modulator of hepatocyte growth factor (HGF) and its receptor c-Met, meaning it appears to amplify a signalling protein the tissue already produces rather than switching a receptor on by itself.

That distinction shapes everything that follows, and it's the fact most online summaries skip. Our team supplies research-grade dihexa to laboratories and independent investigators, and the questions that arrive before procurement are consistently the same three: what the published work actually measured, how identity and purity are verified lot by lot, and what the regulatory status is. All products are sold for laboratory research use only and are not for human consumption.

What is dihexa?

Dihexa is a synthetic angiotensin IV analog, N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, with a molecular weight near 490.6 g/mol. Published preclinical work indexed on PubMed examines it as an HGF/c-Met system modulator in rodent behavioural models and hippocampal cell culture. It is a research chemical, not an approved drug.

The common oversimplification is that dihexa is simply a nootropic peptide. Two problems with that framing: the published record is entirely preclinical, with no human trials, and the reported activity is conditional on endogenous HGF being present in the system, which makes assay design a far larger variable than most write-ups admit. What follows covers the structural chemistry, what the studies measured, laboratory handling, per-lot purity verification, regulatory status, and sourcing.

Compound class, structure, and the mechanism the literature describes

Dihexa is a metabolically stabilised derivative of angiotensin IV, the small fragment of the angiotensin cascade that carries its own distinct central nervous system signalling role. Native angiotensin IV is cleaved rapidly by aminopeptidases, which makes it close to useless as an in vivo probe. The structural answer was to cap both ends of the molecule: an N-terminal hexanoic acid chain and a C-terminal 6-aminohexanoic amide, producing N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Those modifications raise lipophilicity and resistance to enzymatic degradation.

Researchers verifying molecular identity before procurement should match three things against the certificate: the CAS number 1401708-83-5, the molecular formula C26H42N4O5, and a molecular weight near 490.6 g/mol. Any disagreement between the label and the literature values is a procurement stop, not a question to resolve after opening the vial.

Mechanism, in research terms. Hepatocyte growth factor is an endogenous ligand; c-Met is its receptor tyrosine kinase, expressed in hippocampal neurons among many other tissues. Rather than binding c-Met directly, published work reports that dihexa interacts with HGF and facilitates its dimerisation, increasing receptor phosphorylation and downstream PI3K/Akt and MAPK signalling. In hippocampal culture models, that cascade is associated with dendritic spine formation, which is the structural definition of synaptogenesis.

Which gives dihexa an unusual property for a research compound: its activity is conditional on the ligand it modulates. We have had researchers come back puzzled by flat readouts in ligand-depleted systems, and the literature's own framing predicts exactly that. A potentiator with nothing to potentiate does very little.

What the published dihexa literature actually examines

Every peer-reviewed dihexa study is preclinical. The body of work is small, concentrated in a handful of pharmacology groups, and built around two questions: does the compound improve performance in rodent cognition assays, and is that effect dependent on the HGF/c-Met system?

On the first question, McCoy and colleagues evaluated metabolically stabilised angiotensin IV analogs including dihexa in rodent models of scopolamine-induced cognitive deficit, reporting procognitive activity in standard spatial learning paradigms (PubMed). On the second, Benoist and colleagues reported that the procognitive and synaptogenic effects of angiotensin IV-derived peptides were lost when Met signalling was blocked, which is the pharmacological argument that the HGF/c-Met axis carries the effect rather than some unrelated pathway (PubMed).

What the literature does not contain matters just as much. There are no published human clinical trials of dihexa, no human pharmacokinetic profile, and a thin toxicology record. And because c-Met is a well-characterised proto-oncogene, with Met pathway activation studied as a driver in several tumour types, any sustained-exposure model built on this mechanism needs a proliferation readout alongside the behavioural one. That is a literature gap rather than a settled safety finding, and it is the single most common omission from secondhand summaries.

The search index is the honest starting point. Run the compound name through PubMed and read the primary sources before designing anything around it.

Laboratory handling and storage basics

Lyophilised dihexa is stored at −20°C or colder, desiccated, and protected from light. The failure mode for small peptide derivatives in storage is moisture ingress followed by hydrolysis, not sudden visible degradation, so a vial that looks completely normal can still have lost integrity.

Three handling points matter more than the rest in day-to-day lab practice:

• Freeze-thaw cycling is the most common avoidable loss. Preparing aliquots once and returning the parent material to cold storage beats repeated warming of a single container.
• The hexanoic acid and aminohexanoic amide caps make the molecule markedly more lipophilic than native angiotensin IV. Aqueous solubility is limited, which is why in vitro groups typically work from organic stock solutions.
• Short ambient excursions in transit are tolerated far better by lyophilised powder than by material already in solution. Cold-chain anxiety is usually misplaced for shipped powder and entirely justified once the compound is dissolved.

Real Peptides does not publish preparation or administration guidance for dihexa or any other catalogue compound. These are research-use-only materials, and preparation parameters belong to the investigator and the study design, not to a supplier. What we do publish is the milligram content of the vial on the certificate of analysis, which is the figure every concentration calculation, expressed as milligrams per millilitre, has to start from.

How purity is verified, lot by lot

Purity data on dihexa is only meaningful when it is tied to the specific lot in the vial. Reversed-phase HPLC establishes the purity percentage by separating the target peak from synthesis-related impurities, deletion sequences and residual solvent. Mass spectrometry confirms molecular identity by matching the observed mass against the theoretical value. Neither test alone is sufficient: HPLC can produce a clean single peak for the wrong molecule, and mass spectrometry can confirm the right molecule inside an impure preparation.

What a researcher should actually read on a certificate:

• A lot number printed on both the certificate and the vial label, with a test date.
• The chromatogram itself, not just a stated percentage. A number without a trace is an assertion, not data.
• The mass spectrum showing observed versus theoretical mass for dihexa.
• The name of the third-party laboratory that performed the analysis.

Our dihexa is produced through small-batch synthesis with per-lot analysis, and the certificates are published openly rather than supplied on request, viewable in our COA library before anyone places an order. The reason is unglamorous: a certificate produced only on request can quietly be a certificate for a different lot. Publishing removes that ambiguity entirely. In our experience fielding procurement questions, the labs that catch problems early are the ones that compare chromatogram retention times across two lots of the same compound.

Regulatory status and ordering dihexa for research

Dihexa is not an approved drug, not a dietary supplement ingredient, and not an approved investigational product with a published human trial record. It sits in the research chemical category: supplied and held for laboratory use, labelled research use only, and not for human or veterinary consumption. There is no monograph, no approved labelling, and no therapeutic indication attached to it anywhere.

Two practical consequences follow. Institutional procurement and customs teams expect research-use-only documentation to match the shipment, so compound name, CAS number and lot should agree across the label, the certificate and the invoice. Separately, competitive sport bodies generally prohibit substances with no current approval for human therapeutic use under their non-approved substance provisions, so anyone working in a sport-adjacent research context should check the current published list rather than assume.

Ordering runs through our dihexa product page, where the certificate for the shipping lot is linked directly to the listing. Investigators comparing neural-signalling research compounds frequently review Adamax and Selank Liquid Spray alongside it, the wider catalogue sits in our shop, the analytical standard behind every lot is explained on our pure peptides page, and shipping and institutional ordering details are listed on our locations page.

Dihexa vs other research peptides: compound selection comparison

Researchers rarely evaluate one compound in isolation. This table sets dihexa against three compounds that occupy adjacent but genuinely different mechanistic territory, so selection is made on target rather than reputation.

What if: common laboratory scenarios

What if the certificate of analysis has no lot number?

Treat the material as unverified. A certificate without a lot number and test date cannot be matched to the vial in front of you, which means the purity figure describes some batch somewhere, not necessarily this one. Refuse material whose paperwork cannot be traced to the physical label, and compare the chromatogram against a previously accepted lot of dihexa before accepting it into inventory.

What if the vial contents look like a film rather than a white cake?

Photograph it and contact the supplier before opening. Lyophilised peptides sometimes form a thin film instead of a fluffy cake purely because of vial geometry and the freeze-drying cycle, which is cosmetic and common. A sticky, oily or discoloured residue is a different signal, usually pointing to moisture exposure in transit or a compromised stopper seal.

What if the compound shows no activity in a ligand-depleted culture system?

Check whether hepatocyte growth factor is present in the system at all before concluding the material is inactive. Because dihexa is described in the literature as an HGF potentiator rather than an independent agonist, a system stripped of that ligand removes the very thing the compound is supposed to amplify. Confirm identity by mass spectrometry, then reconsider the model rather than the vial.

The unflattering truth about preclinical nootropic claims

Here's the honest answer: the gap between what the dihexa literature shows and what the internet says about dihexa is enormous. A small set of rodent studies and cell-culture work from a handful of pharmacology groups is not a human evidence base, and no amount of repetition on forums converts preclinical synaptogenesis data into a known effect in people. The compound is interesting because the mechanism is genuinely unusual, not because any outcome is established. Researchers who treat it as an open question design better experiments than those who treat it as a settled one.

Dihexa occupies an odd position in peptide research: a novel mechanism, a thin evidence base, and an outsized reputation assembled almost entirely from secondhand summaries of a few primary papers. The HGF/c-Met angle is worth investigating precisely because so little about it is resolved, including the proliferation questions the mechanism itself raises. Anyone sourcing dihexa should start with the certificate and the primary literature, in that order, and let the claims come last. All products are sold for laboratory research use only and are not for human consumption.

Does dihexa cross the blood-brain barrier, and what does the absorption literature report?

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) was designed at Washington State University specifically to solve the delivery problem that limited earlier angiotensin IV analogs. Native Ang IV fragments are rapidly cleaved by aminopeptidases and are poorly lipophilic, so investigators attached a hexanoic acid tail and a 6-aminohexanoic amide cap to raise lipophilicity and shield the termini. Published preclinical work describes the resulting molecule as orally active and able to reach central nervous tissue in rodents, which is why most animal studies use oral or systemic exposure rather than direct central delivery. The chemistry behind these claims is summarized in more depth on the bioavailability and brain delivery overview, and the pharmacokinetic reasoning connects to the compound's persistence profile.

Crossing the barrier is only the first requirement. The literature frames dihexa as acting through the hepatocyte growth factor/c-Met system, so central exposure must be sufficient to engage that pathway in hippocampal and cortical tissue — a point developed in the HGF mimetic mechanism discussion. No validated human pharmacokinetic dataset exists. Statements about brain penetration remain rodent-derived, as the animal research summary makes clear.

How metabolically stable is dihexa compared with the peptides it was derived from?

Stability is the central design claim of this molecule. Angiotensin IV and related hexapeptides are degraded quickly by plasma and tissue peptidases, which historically forced researchers toward central delivery routes in animal work. Dihexa's modifications — an N-terminal acyl chain and a C-terminal amide extension — were introduced to resist exopeptidase cleavage, and published characterization work describes substantially greater resistance to enzymatic breakdown than the parent fragments. This is the practical reason dihexa became a tool compound for studying HGF/c-Met pharmacology rather than remaining a structural curiosity. Analysts examining clearance behavior typically start with the half-life and persistence discussion.

Solution-phase stability and solid-state stability are different questions. Lyophilized material stored cold and protected from moisture and light is generally the most predictable form for long-term inventory, as outlined in the lyophilized powder handling guide. Once in aqueous media, peptide integrity depends on pH, temperature, and time, and should be verified analytically rather than assumed.

Importantly, rodent metabolic stability does not translate automatically across species. That translational gap is the subject of the animal versus human evidence review, and it limits what the available long-term evidence can support.

What cellular endpoints do in vitro dihexa experiments actually measure?

Cell-culture work with dihexa generally focuses on structural and functional markers of synapse formation rather than behavioral proxies. Typical readouts include dendritic spine density and morphology in cultured hippocampal neurons, counts of pre- and postsynaptic marker colocalization (for example synapsin and PSD-95 puncta), electrophysiological measures of synaptic connectivity, and phosphorylation state of c-Met and downstream kinases. Many experiments also test whether effects disappear when c-Met is blocked or when HGF is absent, which is the standard way investigators argue that an observed change is pathway-dependent rather than nonspecific. These designs are catalogued in the in vitro synaptic and neurogenesis findings.

Concentration ranges used in culture are frequently far below those relevant to whole-animal exposure, and the relationship between a picomolar culture effect and a systemic effect in a living organism is not linear. The synaptic neuroscience evidence summary addresses that interpretive gap directly.

For laboratories comparing neurotrophic tool compounds, the same endpoint panel is often applied across molecules, which makes side-by-side evaluation feasible — see the neuroplasticity research overview and the comparative studies summary.

Which animal models appear most often in dihexa research?

Published rodent work has clustered around a few model types. Scopolamine-induced amnesia is used to test whether a compound restores performance after cholinergic disruption. Aged rats serve as a naturalistic model of declining spatial learning. Lesion models, including those targeting cholinergic projections, are used to ask whether a compound supports recovery when circuitry has been damaged. Behavioral assessment generally relies on the Morris water maze or similar spatial navigation tasks, sometimes paired with post-mortem histology for spine density or synaptic markers. The spread of these designs is described in the animal research overview.

Transgenic amyloid models and other dementia-relevant paradigms have also been discussed in the literature around HGF/c-Met pharmacology, which is why dihexa is frequently framed as an Alzheimer's-adjacent research compound. The mechanistic link proposed is synaptic repair rather than plaque clearance, as covered in the memory mechanism discussion.

Model choice constrains conclusions. A compound that reverses a drug-induced deficit has not been shown to alter a progressive neurodegenerative process. The animal versus human evidence comparison covers why that distinction matters when reading summaries.

How does dihexa differ mechanistically from cholinesterase-inhibitor research compounds?

Cholinesterase inhibitors work by slowing the enzymatic breakdown of acetylcholine, raising synaptic availability of an existing neurotransmitter. They are symptomatic in character: the mechanism supports signaling through circuits that still exist but are under-supplied. Dihexa operates on an entirely different axis. It is characterized in the literature as a hepatocyte growth factor mimetic that potentiates HGF signaling at the c-Met receptor tyrosine kinase, a pathway associated with cell survival, dendritic branching, and synapse formation. In other words, one approach amplifies transmission while the other is studied for its effect on structural connectivity. That contrast is laid out in the dihexa and donepezil comparison.

The practical implication for research design is that outcome measures differ. Cholinergic agents are evaluated on rapid task performance; a synaptogenic candidate is evaluated over longer windows with structural endpoints. The limits of extrapolating from either to disease modification are discussed in the mechanism and research limitations review.

Laboratories screening neurotrophic tool compounds often build a short list spanning both mechanisms — see the 2026 alternatives comparison and the early prevention research findings.

What downstream signaling follows c-Met engagement in the dihexa literature?

c-Met is a receptor tyrosine kinase that, when engaged by hepatocyte growth factor, dimerizes and autophosphorylates tyrosine residues in its cytoplasmic tail. Those phosphotyrosines recruit adaptor proteins such as GAB1 and GRB2, which in turn activate the canonical cascades associated with growth factor signaling: PI3K/Akt, which is linked to cell survival; Ras/MAPK/ERK, linked to proliferation and transcriptional change; and PLC-gamma and STAT3 branches. In neurons, the literature associates this signaling with cytoskeletal remodeling, spine formation, and transcription of plasticity-related genes. The transcriptional side is explored in the gene expression and neurotrophic mechanisms overview.

Dihexa is generally described as acting as a positive modulator or potentiator of HGF action rather than as a standalone c-Met ligand, meaning the presence of endogenous HGF matters for the observed effect. That distinction is unpacked in the detailed mechanism of action and in the HGF mimetic mechanism explainer.

Because c-Met is also central to oncology research, pathway selectivity and tissue context are recurring questions in evaluation work, a theme revisited in the 2026 cognitive mechanism review.

What does the intranasal dihexa research literature cover?

Intranasal delivery is a long-standing strategy in neuropeptide research because the olfactory and trigeminal pathways offer routes toward central tissue that partially bypass systemic circulation. For compounds where systemic exposure is inefficient or where peripheral receptor engagement is undesirable, nasal-route studies are a standard part of preclinical characterization. In the dihexa context, this line of inquiry appears alongside oral-route work because the molecule was explicitly engineered for central access; comparing routes helps investigators attribute observed effects to central rather than peripheral activity. The available material on this is collected in the intranasal research and delivery findings.

Route comparison also informs interpretation of exposure data. Oral and nasal studies produce different concentration-versus-time curves in tissue, which is why the oral absorption and brain delivery discussion is usually read alongside the nasal literature rather than in isolation.

No approved clinical product uses this compound by any route. Claims circulating about human nasal use are not supported by registered trial data, a point addressed in the 2026 research status update and the regulatory status explainer.

What safety and interaction topics appear in the dihexa literature?

The honest answer is that the safety dataset is thin. There is no completed human trial program, no published multi-year toxicology package in the public domain comparable to what a regulatory submission would require, and no established no-observed-adverse-effect profile that a laboratory can cite with confidence. What exists are rodent observations recorded alongside efficacy endpoints, which is a weak basis for any general safety statement. The available material is summarized in the research safety profile and contraindications page.

The most frequently raised theoretical concern is c-Met itself. Because this receptor pathway is heavily implicated in cell proliferation and is an active oncology drug target, potentiating it chronically raises questions that have not been resolved in published work. That discussion appears in the side effects research review.

Interaction questions — ethanol exposure, caffeine and other stimulants, and co-administered neuroactive agents in model systems — are mostly unstudied for this compound specifically. Where they are discussed, the reasoning is pharmacological inference rather than direct data, as noted in the alcohol-related research considerations and the caffeine interaction overview. Treat absence of reported harm as absence of evidence.

How long are observation windows in dihexa studies, and why do structural endpoints take time?

Study duration depends on what is being measured. In cell culture, c-Met phosphorylation and early signaling events can be captured within minutes to hours, while spine formation and synaptic marker changes typically require days of exposure before quantification. In rodent behavioral work, acquisition and retention testing in spatial tasks is usually spread across multiple sessions, with histological endpoints collected after the behavioral phase concludes. A synaptogenic hypothesis implies that measurable change requires protein synthesis, cytoskeletal remodeling, and circuit stabilization — processes that unfold over days and weeks, not immediately. The general shape of these windows is described in the brain health timeline overview.

This matters for experimental planning because short observation windows can produce false negatives for a mechanism that is structural rather than transmitter-based, while overly long windows without interim sampling obscure when a change actually began. Staged sampling is the usual compromise, a point developed in the memory outcome timeline discussion and the HGF mimetic timeline summary.

Extended-duration data remain the weakest part of the record; what little exists is reviewed in the long-term evidence page.